Pembridge Resources announces a new focus on the decarbonisation of renewables market. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8,814.00
Bid: 8,813.00
Ask: 8,815.00
Change: 81.00 (0.93%)
Spread: 2.00 (0.02%)
Open: 8,714.00
High: 8,817.00
Low: 8,688.00
Prev. Close: 8,733.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

AstraZeneca Imfinzi's shows positive results in liver cancer treatment

AstraZeneca Imfinzi's shows positive results in liver cancer treatment

19 Jan 22 08:47

AstraZeneca reports positive results from Imfinzi trials

(Sharecast News) - AstraZeneca on Wednesday said its Imfinzi drug combined with chemotherapy reduced the risk of death by 20% in people with advanced biliary tract cancer (BTC) after results from a phase III clinical trial.

19 Jan 22 07:55

AstraZeneca posts robust results for Imfinzi as tract cancer treatment

AstraZeneca posts robust results for Imfinzi as tract cancer treatment

19 Jan 22 06:00

UPDATE 1-EU watchdog urges vaccine developers not to focus only on Omicron

* Pharma groups have been working on upgraded Omicron vaccines* BioNTech CEO has questioned merit of multipurpose shot (Adds background, BioNTech remarks)By Ludwig Burger and Pushkala AripakaJan 18 (Reuters) - The European Union drugs regulator sai...

18 Jan 22 16:34

AstraZeneca's Enhertu granted priority review by US FDA

(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Daiichi Sankyo collaboration Enhertu had been granted priority review by the Federal Drug Administration in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen.

17 Jan 22 07:38

TOP NEWS: New AstraZeneca vaccine results show strong effect on Covid

TOP NEWS: New AstraZeneca vaccine results show strong effect on Covid

13 Jan 22 10:54

LONDON BRIEFING: AIM giant ASOS to move to London Main Market

LONDON BRIEFING: AIM giant ASOS to move to London Main Market

13 Jan 22 08:24

UPDATE 1-New data finds AstraZeneca booster generates higher antibodies against Omicron

(Adds detail from study, background)Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, ...

13 Jan 22 08:07

UPDATE 2-AstraZeneca says early trial data indicates third dose helps against Omicron

(Adds context on other trials and studies)By Pushkala Aripaka and Ludwig BurgerJan 13 (Reuters) - AstraZeneca said on Thursday that preliminary data from a trial showed that its COVID-19 shot, Vaxzevria, generated an increase in antibodies against ...

13 Jan 22 08:07

TOP NEWS: US buys 500,000 doses of Astra's Evusheld Covid antibody

TOP NEWS: US buys 500,000 doses of Astra's Evusheld Covid antibody

12 Jan 22 20:18

India's COVID-19 cases multiply, vulnerable groups given vaccine boosters

NEW DELHI, Jan 10 (Reuters) - India began administering booster doses of COVID-19 vaccine to frontline workers and vulnerable elderly people on Monday, with the fast-spreading Omicron variant fuelling an almost eight-fold rise in daily infections...

10 Jan 22 04:39

TOP NEWS: AstraZeneca's subsidiary enters agreement with Neurimmune

TOP NEWS: AstraZeneca's subsidiary enters agreement with Neurimmune

7 Jan 22 09:47

AstraZeneca strikes collaboration and license agreement with Neurimmune

(Sharecast News) - Drugmaker AstraZeneca's Alexion rare diseases unit has inked an exclusive collaboration and license agreement with Neurimmune that will see the pair develop and commercialise NI006, an investigational human monoclonal antibody for the treatment of transthyretin amyloid cardiomyopathy.

7 Jan 22 07:07

UPDATE 1-Tie pharma CEO pay to fair global COVID-19 vaccine access, investors say

(Updates with reaction from Johnson & Johnson)By Toby SterlingAMSTERDAM, Jan 6 (Reuters) - A group of institutional investors representing $3.5 trillion in assets under management on Thursday called on pharmaceutical companies to link their execut...

6 Jan 22 15:59

UPDATE 2-Tie pharma CEO pay to fair global COVID-19 vaccine access, investors say

(Updates with reaction from Pfizer)By Toby SterlingAMSTERDAM, Jan 6 (Reuters) - A group of institutional investors representing $3.5 trillion in assets under management on Thursday called on pharmaceutical companies to link their executives' pay t...

6 Jan 22 15:59

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.